Form 4 RESMED INC For: Aug 10 Filed by: Sandercock Brett
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'
August 15, 2022 6:31 AM EDTCLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy (1) to Outperform (2) with a price target of AUD38.40.
The analyst comments "ResMed (RMD) delivered another solid result in 4Q22, with revenues (ex-Covid at pcp) +10% CC to US$914.7m. This was in-line... More



